title: Does the MOSES trial establish superiority of AT1-receptor blockers over dihydropyridine/calcium antagonists in secondary stroke prevention?
authors.forename: Albert
authors.initials: A
authors.lastname: Fournier
authors.forename: Gabriel
authors.initials: G
authors.lastname: Choukroun
authors.forename: Santhi Samy
authors.initials: SS
authors.lastname: Modeliar
authors.forename: Olivier
authors.initials: O
authors.lastname: Godefroy
authors.forename: Jean-Michel
authors.initials: JM
authors.lastname: Achard
authors.forename: Jiguang
authors.initials: J
authors.lastname: Wang
authors.forename: Franz
authors.initials: F
authors.lastname: Messerli
mesh_terms: D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D017209:Apoptosis; D001794:Blood Pressure; D002118:Calcium / Q000037:antagonists & inhibitors*; D002318:Cardiovascular Diseases / Q000473:pathology; D004095:Dihydropyridines / Q000627:therapeutic use*; D006801:Humans; D015995:Prevalence; D012008:Recurrence; D012306:Risk; D020521:Stroke / Q000188:drug therapy / Q000473:pathology / Q000517:prevention & control*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D004095:Dihydropyridines; C038806:1,4-dihydropyridine; D002118:Calcium